PF-Atlas › Clinical Trials › NCT00517933
Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis
Sildenafil Citrate · Phase 3
Registry ID
NCT00517933
Phase
Phase 3
Status
Completed
Drug / intervention
Sildenafil Citrate
Sponsor
Duke University
Start
2007-08
Enrollment
180
Locations
13
About this trial
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that affects an individual's ability to breathe. This study will evaluate the effectiveness of sildenafil, a medication that increases blood flow to the lungs, at improving breathing function, exercise capacity, and quality of life in people with advanced IPF.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT00517933 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.